Anti-Oxidants, there is no evidence that they are of use

Plemel JR, Juzwik CA, Benson CA, Monks M, Harris C, Ploughman M. Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review.
Mult Scler. 2015 Aug 18. pii: 1352458515601513. [Epub ahead of print] 

BACKGROUND: Anti-oxidant compounds that are found in over-the-counter (OTC) supplements and foods are gaining interest as treatments formultiple sclerosis (MS). They are widely used by patients, sometimes without a clear evidence base.
OBJECTIVE:We conducted a systematic review of animal and clinical research to determine the evidence for the benefits of OTC anti-oxidants in MS.
METHODS:Using predefined criteria, we searched key databases. Two authors scrutinized all studies against inclusion/exclusion criteria, assessed study risk-of-bias and extracted results.
RESULTS: Of the 3507 titles, 145 met criteria and included compounds, α(alpha)-lipoic acid (ALA), anti-oxidant vitamins, Ginkgo biloba, quercetin, resveratrol and epigallocatechin-3-gallate (ECGC). The strongest evidence to support OTC anti-oxidants was for compounds EGCG and ALA in animal models; both consistently showed anti-inflammatory/anti-oxidant effects and reduced neurological impairment. Only vitamin E, Ginkgo biloba and ALA were examined for efficacy in pilot clinical trials with either conflicting evidence or evidence of no benefit.
CONCLUSION:OTC anti-oxidants EGCG and ALA show the most consistent benefit, however only in preclinical studies. There is no evidence that they alter MS relapses or progression. Future work should focus on testing more of these therapies for clinical efficacy before recommending them to MS patients
.

You recently asked about doing meta analysis of animal studies to get an idea if they are of use in the translational process.

I answered that perhaps, but you need a critical eye. 

So here we have such a thing and it suggests that animal studies show that some anti-oxidants work but when tried in human trials they fail, as may be anticipated for a nutriceutical 

(I am not saying nutriceuticals have no value, but they are not DMT. Nutriceuticals are unlikely to be trialed properly because there is no money to be made and so studies are small, underpowered and invariably inconclusive). 

Remember there is a publication bias for positive data in animal studies and if you give enough water to animals it will stop their EAE. 

The first question that should be asked is whether the animals got a human equivalent dose of the agent. If it is above the human equivalent dose then the "positive data" are meaningless for the translatability and if the doses are too high they should be excluded from the analysis.

Tooth paste will be immunosuppressive to animals if you give enough of it, just like loud noises are immunosuppressive. It's "the building-site effect" put an animal in a building site and EAE stops.

Labels: